Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
暂无分享,去创建一个
D. Chan | I. Thompson | A. Partin | J. Moul | S. Srivastava | Zhen Zhang | L. Sokoll | J. Rosenzweig | Y. Yasui | B. Adam | M. Winget | Ziding Feng | L. Cazares | O. J. Semmes | Gunjan Malik | D. McLerran | W. Grizzle | S. Srivastava | W. Bigbee | Liu Zhu | L. Bañez | D. Campos | E. Izbicka | J. Kagan | P. Prasanna | M. Welsh | Nicole White | Jason M. Rosenzweig | O. Semmes | D. Chan | I. Thompson
[1] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[2] O John Semmes,et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] Jeffrey S. Morris,et al. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..
[4] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[5] G. Wright,et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.
[6] Kaushik Ghosh,et al. A New Method of Predicting US and State‐Level Cancer Mortality Counts for the Current Calendar Year , 2004, CA: a cancer journal for clinicians.
[7] D. Ransohoff. Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.
[8] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[9] Ruth Etzioni,et al. Early detection: The case for early detection , 2003, Nature Reviews Cancer.
[10] E. Petricoin,et al. Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.
[11] K. Kozak,et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] D. Seligson,et al. Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.
[13] Sudhir Srivastava,et al. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. , 2004, Urologic oncology.
[14] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[15] C. Paweletz,et al. New approaches to proteomic analysis of breast cancer , 2001, Proteomics.
[16] P. Schellhammer,et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.
[17] X. Xiao,et al. Development of Proteomic Patterns for Detecting Lung Cancer , 2004, Disease markers.
[18] D. Chan,et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.
[19] L. Liotta,et al. Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer , 2002, Disease markers.
[20] D. McCarthy,et al. Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.
[21] E. Diamandis. Re: diagnostic potential of serum proteomic patterns in prostate cancer. , 2004, The Journal of urology.
[22] J. Potter,et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. , 2003, Biostatistics.
[23] William E Grizzle,et al. Clarification in the point/counterpoint discussion related to surface-enhanced laser desorption/ionization time-of-flight mass spectrometric identification of patients with adenocarcinomas of the prostate. , 2004, Clinical chemistry.
[24] Bao-Ling Adam,et al. Diagnostic potential of serum proteomic patterns in prostate cancer. , 2003, The Journal of urology.
[25] A. Vlahou,et al. A novel approach toward development of a rapid blood test for breast cancer. , 2003, Clinical breast cancer.
[26] Y. Yasui,et al. An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers , 2003, Journal of biomedicine & biotechnology.
[27] J. Moul,et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] H. Kumar. Re: histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: clinical implications. , 2004, The Journal of urology.
[29] T. Zhukov,et al. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. , 2003, Lung cancer.
[30] Min Zhan,et al. A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.
[31] P. Schellhammer,et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.
[32] T. Yip,et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. , 2003, Clinical chemistry.
[33] D. R. Lewis,et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. , 2003, The oncologist.
[34] O John Semmes,et al. Serum Protein Profiles to Identify Head and Neck Cancer , 2004, Clinical Cancer Research.
[35] K. Lillemoe,et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.
[36] Erika Check,et al. Proteomics and cancer: Running before we can walk? , 2004, Nature.
[37] B. Adam,et al. Identification of patients with head and neck cancer using serum protein profiles. , 2004, Archives of otolaryngology--head & neck surgery.
[38] E. Diamandis. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.
[39] D. Chan,et al. Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.
[40] T. Kang,et al. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons , 2003, Proteomics.